MacFadden: Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications [Spironolactone]

Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications

MacFadden et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide.., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Mar 2022 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 26,121 cases and 2,369,020 controls ≥65yo in Canada, showing lower cases with chronic use of spironolactone.

Important missing comments or errors? Let us know.

This study includes HCQ, metformin, famotidine, spironolactone, vitamin B9, acetaminophen, and fluvoxamine.

risk of case, 7.0% lower, OR 0.93, p = 0.008, RR approximated with OR.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

MacFadden et al., 29 Mar 2022, retrospective, Canada, peer-reviewed, 9 authors, study period 15 January, 2020 - 31 December, 2020.

Contact: dmacfadden@toh.ca.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Spironolactone All

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit